Access a range of cancer related small molecules including inhibitors, the popular Kinase Chemogenomic Set (KCGS) and many more, from leading cancer institutes, laboratories and universities worldwide.
NC9 – Transglutaminase 2 Inhibitor small molecule (tool compound)
Cat. #:
159669
Sub-type:
Inhibitor
Availability:
Please enquire for quantities and pricing
Application:
Has been shown to block TG2 transamidation activity inside cancer stem cells (SCC13 cells) resulting in abolished transamidase activity. Inhibitor blocks EMT and kills cancer stem cells. In mesothiolioma cancer stem cells, inhibition of TG2 reduces migration (invasion), and appears to increase markers of apoptosis.
VA4 – Tranglutaminase 2 Inhibitor small molecule (tool compound)
Cat. #:
159670
Sub-type:
Inhibitor
Availability:
Please enquire for quantities and pricing
Application:
Has been shown to block TG2 transamidation activity inside cancer stem cells (SCC13 cells) resulting in abolished transamidase activity. Inhibitor blocks EMT, invasion and kills cancer stem cells. In mesothiolioma cancer stem cells, inhibition of TG2 reduces migration (invasion), and appears to increase markers of apoptosis.
The inventors have demonstrated its radical scavenging and antiproliferative effects on three widely used and commercially available cell lines: MCF7, MDA-MB-468, MDA-MB-231.
Tin Tungstate Nanoparticles Beta-SnWO4 small molecule (tool compound)
Cat. #:
160389
Sub-type:
Nanoparticle
Availability:
Please enquire for quantities and pricing
Application:
Used to treat tumours in BALB/C mice orthotopically inoculated with the 4T1 breast cancer cell line. Reduced lymph node metastases.Killed 4T1 cells in vitro.
Bartonella quintana-derived toll-like receptor 4 antagonist small molecule (tool compound)
Cat. #:
160531
Sub-type:
Inhibitor
Availability:
Please enquire for quantities and pricing
Application:
In Malgorzata-Miller et al Sci. Rep. 6, 34221; doi: 10.1038/srep34221 (2016):
Wild type mice were injected intraperitoneally (i.p.) with either PBS, or B. quintana LPS 100âÎźg/mouse. After 30âminutes 10 mice of each group were injected with PBS and 10 mice were injected i.p. E. coli LPS 1âÎźg per mouse (Escherichia coli LPS 055:B5 Sigma Chemical Co., St Louis, MI, USA)â+âD-galactosamine 14âmg per mouse. Survival of all 4 groups (PBSâ+âPBS, B. quintana LPSâ+âPBS, PBSâ+âE. coli LPS/D-galactosamine and B. quintana LPSâ+âE. coli LPS/D-galactosamine was assessed for 10 days.
Please ensure you use your organisation email address rather than personal where possible, as this helps us locate your organisation in our system faster.
Please note we may take up to three days to respond to your enquiry.
CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.
